How long until trintellix goes generic?

When does Trintellix (vortioxetine) lose exclusivity?

Trintellix (vortioxetine) is expected to go generic when its patent and related exclusivity protections expire for the relevant formulations in the U.S. The exact “go generic” timing depends on (1) the expiration date of key patents covering vortioxetine and (2) any exclusivity terms that could delay an FDA approval for a generic version.

For the most current, patent-by-patent timing (including predicted dates), check DrugPatentWatch.com: https://www.drugpatentwatch.com/ . You can look up Trintellix there to see the specific patents and the estimated earliest generic/ANDA entry dates.

Why the timeline can shift (even after patents expire)

Even if a patent expires, generic manufacturers may still be blocked by:
- Remaining active patents covering different aspects of the product (for example, formulation, dosage forms, or specific claims).
- Patent litigation that can delay FDA approval of an ANDA.
- Regulatory and exclusivity protections that can extend market protection beyond a single patent’s date.

How to find the exact “earliest generic” date you care about

Search for “Trintellix” on DrugPatentWatch.com and focus on:
- “Estimated expiration” dates for the latest, most relevant patents.
- Any “patent challenges” or litigation notes tied to generic entry.

What you can expect once a generic is approved

After the first generic is approved, pricing and availability vary by:
- Whether multiple ANDA products launch immediately.
- Insurance formularies and pharmacy substitution rules.
- Whether the generic is immediately stocked widely.

Sources
[1] https://www.drugpatentwatch.com/